Urol. praxi. 2021;22(3):109-113 | DOI: 10.36290/uro.2021.019

Conservative therapy of neurogenic lower urinary tract dysfunctions - 2nd part

MUDr. Miroslav Záleský, Ph.D.
Urologické oddělení ÚVN, Praha
Urologická klinika FNKV a 3. LF UK, Praha

Possibilities of pharmacological and non-pharmacological therapy of neurogenic lower urinary tract dysfunctions are presented. Neurogenic lesions leading to lower urinary tract dysfunctions can be divided into suprapontine, infrapontine, and sacral and peripheral lesions. Due to the complexity of neurogenic disorders, it is necessary to base treatment on urodynamics results. The aim of therapy of neurogenic lower urinary tract dysfunctions is to protect the upper urinary tract, achieve continence, ensure adequate evacuation of bladder, and improve patients' quality of life. Combination of non-pharmacological treatment and pharmacotherapy is usually applied. Intermittent catheterization is cornerstone of non-pharmacological treatment lower urinary tract dysfunction with inadequate evacuation of bladder. Oral anticholinergics dominates in pharmacotherapy of detrusor overactivity. Intravesical application of botulinum toxin acquires an increasing role in case of insufficient effect of oral anticholinergics.

Keywords: neurogenic dysfunction of the lower urinary tract, urodynamics, intermittent catheterization, anticholinergics, botulinum toxin.

Received: May 8, 2021; Revised: May 8, 2021; Accepted: May 10, 2021; Prepublished online: May 10, 2021; Published: October 21, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Záleský M. Conservative therapy of neurogenic lower urinary tract dysfunctions - 2nd part. Urol. praxi. 2021;22(3):109-113. doi: 10.36290/uro.2021.019.
Download citation

References

  1. Zachoval R, Záleský M, Lukeš M, et al. Funkce dolních mocových cest a jejich poruchy. Čes Fyziol. 2000; 49: 134-144.
  2. Zachoval R. Neurofyziologie a neurofarmakologie dolních močových cest. Nakladatelství Art Print Studio; 2001.
  3. Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur Urol 2016; 69(2): 324-333. Go to original source... Go to PubMed...
  4. EAU Guidelines on Neuro-Urology 2020. [Internet]. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Neuro-Urology-2020.pdf.
  5. Guo G, Kang Y. Effectiveness of neuromuscular electrical stimulation therapy in patients with urinary incontinence after stroke. Medicine (Baltimore) 2018; 97(52): 1-5. Go to original source... Go to PubMed...
  6. Brusa L, Finazzi Agrò E, Petta F, et al. Effects of inhibitory rTMS on bladder function in Parkinson's disease patients. Mov Disord 2009; 24(3): 445-448. Go to original source... Go to PubMed...
  7. Centonze D, Petta F, Versace V, et al. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. Mult Scler. 2007; (2): 269-271. Go to original source... Go to PubMed...
  8. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972; 107(3): 458-461. Go to original source... Go to PubMed...
  9. Záleský M. Konzervativní terapie non-neurogenních dysfunkcí dolních močových cest. Urol. praxi 2021; 22(2): 65-69. Go to original source...
  10. Schröder A, Albrecht U, Schnitker J, et al. Efficacy, safety, and tolerability of intravesically administered 0.1 % oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial. Neurourol Urodyn 2016; 35(5): 582-588. Go to original source... Go to PubMed...
  11. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med 2013; 36(5): 402-419. Go to original source... Go to PubMed...
  12. Návrh postupu při preskripci preparátu BOTOX - [Internet]. Česká urologická společnost. Available from: https://www.cus.cz/pro-odborniky/o-spolecnosti/dulezite-informace/navrh-postupu-pri-preskripci-preparatu-botox/.
  13. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004; 172(1): 240-243. Go to original source... Go to PubMed...
  14. Ladi-Seyedian S-S, Nabavizadeh B, Sharifi-Rad L, Kajbafzadeh A-M. Pharmacological treatments available for the management of underactive bladder in neurological conditions. Expert Rev Clin Pharmacol 2018; 11(2): 193-204. Go to original source... Go to PubMed...
  15. Apostolidis A. Taming the cannabinoids: new potential in the pharmacologic control of lower urinary tract dysfunction. Eur Urol 2012; 61(1): 107-109. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.